LONDON AND HONG KONG, Nov 10, 2022 – (ACN Newswire) – Prenetics Global Limited (NASDAQ: PRE) (Prenetics or the Company), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the third quarter ended September 30, 2022. Third Quarter 2022 and Recent Highlights: — Reported third quarter 2022 revenue of US$80 million– Reported loss from operations of US$9 million, adjusted earnings1 of US$21 million and adjusted EBITDA2 of US$27 million in the third quarter– Achieved gross margin of 59% in the third quarter– Appointed Professor Robert Harris, f…
